JW Shinyak Corporation (067290) - Total Assets
Based on the latest financial reports, JW Shinyak Corporation (067290) holds total assets worth ₩64.75 Billion KRW (≈ $43.88 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 067290 total equity for net asset value and shareholders' equity analysis.
JW Shinyak Corporation - Total Assets Trend (2007–2024)
This chart illustrates how JW Shinyak Corporation's total assets have evolved over time, based on quarterly financial data.
JW Shinyak Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
JW Shinyak Corporation's total assets of ₩64.75 Billion consist of 45.4% current assets and 54.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩7.83 Billion | 12.4% |
| Accounts Receivable | ₩10.72 Billion | 17.0% |
| Inventory | ₩9.47 Billion | 15.0% |
| Property, Plant & Equipment | ₩19.08 Billion | 30.3% |
| Intangible Assets | ₩5.02 Billion | 8.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how JW Shinyak Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see JW Shinyak Corporation market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: JW Shinyak Corporation's current assets represent 45.4% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2024, up from 5.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 42.0% in 2007.
- Asset Diversification: The largest asset category is property, plant & equipment at 30.3% of total assets.
JW Shinyak Corporation Competitors by Total Assets
Key competitors of JW Shinyak Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.65 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
JW Shinyak Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 1.21 | 0.87 |
| Quick Ratio | 0.81 | 0.93 | 0.48 |
| Cash Ratio | 0.00 | 0.27 | 0.00 |
| Working Capital | ₩6.38 Billion | ₩7.34 Billion | ₩-5.06 Billion |
JW Shinyak Corporation - Advanced Valuation Insights
This section examines the relationship between JW Shinyak Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.11 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | ₩63.04 Billion |
| Market Capitalization | $56.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values JW Shinyak Corporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: JW Shinyak Corporation's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for JW Shinyak Corporation (2007–2024)
The table below shows the annual total assets of JW Shinyak Corporation from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩63.04 Billion ≈ $42.72 Million |
-3.94% |
| 2023-12-31 | ₩65.62 Billion ≈ $44.47 Million |
-30.26% |
| 2022-12-31 | ₩94.09 Billion ≈ $63.77 Million |
+2.27% |
| 2021-12-31 | ₩92.00 Billion ≈ $62.35 Million |
-4.49% |
| 2020-12-31 | ₩96.33 Billion ≈ $65.28 Million |
-29.61% |
| 2019-12-31 | ₩136.85 Billion ≈ $92.74 Million |
+25.32% |
| 2018-12-31 | ₩109.21 Billion ≈ $74.01 Million |
-11.47% |
| 2017-12-31 | ₩123.36 Billion ≈ $83.60 Million |
-14.10% |
| 2016-12-31 | ₩143.61 Billion ≈ $97.32 Million |
+12.47% |
| 2015-12-31 | ₩127.68 Billion ≈ $86.53 Million |
+0.54% |
| 2014-12-31 | ₩126.99 Billion ≈ $86.06 Million |
+0.53% |
| 2013-12-31 | ₩126.32 Billion ≈ $85.60 Million |
+9.61% |
| 2012-12-31 | ₩115.25 Billion ≈ $78.10 Million |
+12.12% |
| 2011-12-31 | ₩102.79 Billion ≈ $69.66 Million |
+127.08% |
| 2008-12-31 | ₩45.27 Billion ≈ $30.68 Million |
-7.34% |
| 2007-12-31 | ₩48.85 Billion ≈ $33.11 Million |
-- |
About JW Shinyak Corporation
JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesi… Read more